A significant positive modulation of the innate immune pathway genes (STING and MAVS) was demonstrated in SCLC cell models using sequential chemotherapy and RT treatments in vitro, suggesting a possible role of TRT in ES-SCLC patients treated with chemoimmunotherapy. This evidence concerns the gene STING1 and small cell lung carcinoma.